Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
Part of paid clinical trials in La Jolla, California.
- Sponsor
- Faeth Therapeutics
- Study ID
- NCT06463028
- Phase
- PHASE2
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Sapanisertib — DRUGOral
- Serabelisib — DRUGOral
- Paclitaxel — DRUGInfusion
Study Details
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Key Dates
- Start date
- Dec 12, 2024
- Status verified
- Dec 2025
- Primary completion
- Sep 30, 2028
- Completion
- Sep 30, 2029
Study Design
- Enrollment
- 40 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: sapanisertib and serabelisib (PIKTOR) with paclitaxelSubjects will receive doses of sapanisertib and serabelisib (PIKTOR) administered orally and paclitaxel administered intravenously.
Primary Outcome Measure
Objective Response Rate (ORR) [ Time Frame: Up to 2 years ]
Central Contacts
- Medical Monitor(708)406-9282
Locations (18)
Find similar trials in La Jolla, CA
By condition
By specialty
By research site
UC San Diego Moores Cancer Center· La Jolla, CAUniversity of California, San Francisco (UCSF)· San Francisco, CAMount Sinai Comprehensive Cancer Center· Miami Beach, FLFlorida Cancer Specialists, North· St. Petersburg, FLFlorida Cancer Specialists, East· West Palm Beach, FLMaryland Oncology Hematology, P.A.· Brandywine, MD
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersPHASE1/PHASE2 · Recruiting · Regeneron Pharmaceuticals · Birmingham, Alabama
- Vaginal Cuff Brachytherapy Fractionation StudyPHASE3 · Recruiting · Kara Romano, MD · Baltimore, Maryland